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ing docetaxel, an H3 and a BTA. Docetaxel-treated patients are younger than those 
receiving an H3.
PCN21
EvolviNg TrEaTmENT PaTTErNs iN mETasTaTiC mElaNoma iN CaNada
Koa H., Merali T., Ali A.
Drug Intelligence Inc., Toronto, ON, Canada
Objectives: Treatment for metastatic melanoma (mM) has evolved rapidly with 
the recent approval and reimbursement of new therapies. At the end of 2013, four 
new therapies, vemurafenib, ipilimumab, drabrafenib and trametinib were avail-
able for treatment of specific groups of patients with metastatic melanoma. Our 
objective is to compare the drug treatment sequences at centers in Canada during 
the time periods prior to and after availability of the new therapies. MethOds: The 
study used ONCO-CAPPS, a proprietary database of patient chart abstractions col-
lected through regular survey of physician panels. The data includes demographic 
details as well as disease markers, and a summary of the patients’ cancer treat-
ments from the time of diagnosis. Data from the time periods 2007 and 2013 were 
used to identify patients with metastatic melanoma and document their sequence 
of treatments. Conventional treatments include the older therapies: dacarbazine 
(DTIC), carboplatin-paclitaxel, lomustine, interferon and interleukin-2. Results: 
In 2007, 53 patients with mM were treated in first-line (1st) line and the major-
ity received a conventional therapy. Twenty-one of these patients progressed and 
received second-line (2nd) line therapy; 62% of them received a conventional therapy 
while 38% received an investigational agent. In 2013, 157 patients with mM were 
treated in 1stline; 47%, 10% and 43% of these received a conventional therapy, an 
investigational agent and a new therapy, respectively. Of those who progressed, 
18%, 11% and 71% received a conventional therapy, an investigational agent and a 
new therapy, respectively. cOnclusiOns: With the availability of newer options, a 
greater proportion of patients are being treated with these agents. The proportion 
of patients being treated with an investigational agent in 2nd line has decreased. 
Older agents continue to be used and the use of the newer therapies is dependent 
on patient characteristics and reimbursement guidelines.
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ThE EffECT of grouNdbrEakiNg mEdiCal ThEraPy oN ThE iNCidENCE of 
disEasE: a CasE sTudy of riTuximab aNd NoN-hodgkiN’s lymPhoma
Rotella P.1, Teltsch D1, Swain R.1, Ishak K.J.2, Reynolds M.W.1, Robinson D.Jr.3
1Evidera, Lexington, MA, USA, 2Evidera, St-Laurent, QC, Canada, 3Janssen Global Services, 
Malvern, PA, USA
Objectives: The development of new medical therapies can have a profound effect 
on the epidemiology of a disease, especially when that development represents the 
first efficacious treatment. Rituximab was the first monoclonal antibody therapy 
for cancer, gaining FDA approval in 1997 in the United States (US) to treat non-
Hodgkin’s lymphoma (NHL). Rituximab’s positive impact on mortality has been 
well-documented. The potential effect of rituximab on the incidence of NHL is 
necessary to understand the full epidemiological impact of the drug. This study 
aimed to investigate that effect. MethOds: Age-adjusted incidence rates of NHL 
were modeled over time using Poisson regression, allowing a different slope for 
change in yearly rate before and after 1997. This allows assessment of whether 
the incidence rate was accelerating, decelerating, or did not change after 1997. To 
determine the optimal change-point for incidence of NHL, the model was repeated 
for each year within the study period and Akaike information criteria (AIC) were 
compared. The year with the lowest AIC was considered the optimal change-point. 
This analysis utilized the Surveillance, Epidemiology, and End Results (SEER) 9 inci-
dence data, which covers the time period 1973 -2010 (accessed using SEER*Stat 
software, version 8.1.2). Results: From 1973 -2010, there were 239,118 total cases 
of NHL documented in SEER. The model estimated an increase in incidence of 1.9% 
per year prior to 1997, compared to an estimated increase of only 0.5% per year 
from 1997 -2010. Comparison of AIC’s identified 1990 as the optimal change-point 
(annual incidence increase pre-1990: 2.4%; post-1990: 0.8%). cOnclusiOns: The 
incidence of NHL in the US has been increasing fairly steadily since 1973, though it 
has been increasing more slowly in recent years, and nearly stabilized after 1997. 
In fact, this deceleration appears to have started around 1990, prior to the approval 
and availability of rituximab.
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iNvEsTigaTiNg survival assoCiaTEd wiTh aNgioTENsiN bloCkadE 
agENTs iN PaTiENTs wiTh PaNCrEaTiC CaNCEr
Karagiannis T.1, Keith S.W.2, Rabinowitz C.2, Louis D.3, Maio V.2
1Jefferson School of Population Health, Philadelphia, PA, USA, 2Thomas Jefferson University, 
Philadelphia, PA, USA, 3Jefferson Medical College, Philadelphia, PA, USA
Objectives: Pancreatic cancer is the 4thleading cause of adult cancer mortality 
in the United States with a 5-year survival rate of approximately 6%. ACE inhibi-
tors and ARBs have been shown to inhibit tumor angiogenesis in pancreatic cells 
in both in-vitro and murine model studies. Previous research studies exploring a 
relationship between these agents and patients with pancreatic cancer used several 
different methods leading to unclear results. We conducted a large population-based 
study to examine overall survival differences in patients with pancreatic cancer 
taking ACE inhibitors or ARBs. MethOds: We used the Italian Emilia-Romagna 
Region (RER) health care database to conduct a retrospective cohort study following 
approximately 4 million adults (≥ 18) from 2003 to 2011. The RER database captures 
fully-linkable demographic, hospital discharge, outpatient pharmacy, and proce-
dure codes for all residents of the region. Patients were classified by resection and 
metastases based on surgical procedures and secondary malignancies. We used a 
Cox-proportional hazard model for each time-dependent medication exposure to 
minimize potential immortal-time-bias. Results: We identified a total of 8,281 
patients diagnosed with pancreatic cancer from 2003 to 2011 in the RER. After 
adjusting for covariates, the Cox-proportional hazards model using time-dependent 
exposure suggested that, among pancreatic cancer patients, those exposed to ACE 
Objectives: To characterize safety and efficacy outcomes of albumin-bound pacli-
taxel (nab-paclitaxel) in MBC in the United States since its approval in 2005 using 
health insurance claims data. MethOds: A retrospective claims analysis was con-
ducted using the Optum Research Database (United Health affiliate). The analysis 
included females aged ≥ 18 years diagnosed with MBC (≥ 2 claims of BC diagnosis 
separated by ≥ 30 days and ≥ 2 claims of metastatic spread) prior to nab-paclitaxel 
initiation who had complete medical coverage and pharmacy benefits, ≥ 6 months 
of continuous enrollment in a US health insurance plan from January 2005 through 
September 2012, no other primary malignancy, and no prior nab-paclitaxel therapy. 
Data were supplemented by Social Security Death Index sources. Cohorts were 
determined by line of therapy, nab-paclitaxel regimen, and schedule. Descriptive 
statistics were used to characterize outcomes. Endpoints included time to treat-
ment discontinuation (TTD), overall survival (OS), and safety. Results: Among 
664 eligible patients, most were between 40-69 years of age (88%) and had received 
nab-paclitaxel as ≥ second-line therapy (74%), monotherapy (61%), and weekly (71%). 
Bevacizumab (22%) and HER2-targeted therapies (9%) were used as combination 
partners. Median TTD and OS were 6.1 and 17.4 months, respectively. By line of 
therapy (first, second, and ≥ third), TTD was 7.1, 6.6, and 5.3 months and OS was 
22.7, 17.4, and 15.1 months. Median OS was similar when nab-paclitaxel was used 
in combination or as monotherapy (18.7 and 16.8 months) and weekly or every 3 
weeks (18.6 and 17.4 months). No new safety signals were observed. cOnclusiOns: 
Outcomes in this real-world patient population were consistent with clinical trial 
data, affirming the effectiveness and manageable safety profile of nab-paclitaxel in 
patients with MBC. This analysis will also help evaluate the benefit of nab-paclitaxel 
in patients aged ≥ 70 years.
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CosT-uTiliTy aNalysis of dabrafENib/TramETiNib CombiNaTioN (d+T) 
for brafv600 muTaTioN-PosiTivE mETasTaTiC mElaNoma (mm) from ThE 
uNiTEd kiNgdom (uk) NaTioNal hEalTh sErviCE (Nhs) PErsPECTivE
Lee N.R.1, Lee S.H.1, Kim J.1, Son S.K.1, Seo H.J.2, Park D.A.1
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Chosun 
University, Gwangju, South Korea
Objectives: Estimate the incremental cost-effectiveness ratio (ICER) of D+T versus 
vemurafenib and dacarbazine for BRAFV600 mutation-positive MM from the UK NHS 
perspective. MethOds: A partitioned-survival model with 3 states (progression-
free survival [PFS], post-progression survival, and death) and a lifetime horizon 
was developed. Treatment benefits were measured as gains in quality-adjusted 
life-years (QALYs). PFS and overall survival (OS) were derived from indirect treatment 
comparisons (ITCs) of D+T (from the Phase II BRF113220 study) versus vemurafenib 
(BRIM-3) and dacarbazine (BREAK-3). Latest OS data were adjusted for confounding 
effects of treatment switching, permitted upon progression in all studies. Safety 
data were from aforementioned trials. Costs were from the literature, a physician 
survey, and assumptions. Costs of medications to the NHS (incorporating avail-
able patient-access schemes), post-study anticancer therapy, routine and adverse 
event (AE) management, treatment initiation, and death were included. Utility data 
for D+T were derived from BREAK-3, with adjustment for differences in response 
and incidence of AEs. Deterministic and probabilistic sensitivity analyses were 
performed. Results: ITCs showed D+T significantly improved PFS versus vemu-
rafenib (hazard ratio [HR] 0.38; 95% CI, 0.19–0.74) and dacarbazine (0.14; 0.08–0.28) 
and suggested improved OS, although not statistically significant (0.42; 0.09–1.97 
versus vemurafenib and 0.26; 0.05–1.27 versus dacarbazine). Treatment with D+T 
was associated with a gain in QALYs versus vemurafenib and dacarbazine. The 
ICER for D+T was £50,603/QALY versus vemurafenib and £49,804/QALY versus dac-
arbazine. cOnclusiOns: Based on results of a Phase II trial and an ITC, D+T offers 
improved PFS and OS versus vemurafenib and dacarbazine. Further, considering 
NICE’s criteria for life-extending, end-of-life treatments, D+T may be cost-effective 
compared with vemurafenib, the NHS’s current standard of care for patients with 
BRAFV600 mutation-positive MM, although conclusions must await ongoing model-
ling on the basis of the Phase III, COMBI-D trial.
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havE NEw ThEraPiEs ChaNgEd ThE faCE of mETasTaTiC CasTraTE-
rEsisTaNT ProsTaTE CaNCEr TrEaTmENT iN CaNada?
Koa H., Merali T., Ali A.
Drug Intelligence Inc., Toronto, ON, Canada
Objectives: Treatment for metastatic castrate-resistant prostate cancer (mCRPC) 
has evolved rapidly with the introductions of abiraterone, denosumab and cabazi-
taxel in 2011 and enzalutamide in 2013 and the subsequent funding of these 
new agents. Our objective is to describe the treatments used after a diagnosis of 
mCRPC in Canada. MethOds: The study used ONCO-CAPPS, a proprietary database 
of patient chart abstractions collected through regular survey of physician panels. 
The data includes the stage of the disease along with a summary of treatment 
from diagnosis. Data from 2011 and 2013 were used to identify patients with 
mCRPC and to describe the treatments used. Hormone therapies are grouped as fol-
lows: H1 is Luteinizing-Hormone-Releasing Hormone analogs, H2 is anti-androgens 
while H3 is ketoconazole, prednisone, abiraterone or enzalutamide. Chemotherapy 
includes docetaxel and cabazitaxel. Pamidronate, zoledronic acid or denosumab are 
bone-targeted agents (BTA). Results: All patients with mCRPC are treated with 
a combination of hormones, with or without docetaxel and/or a BTA. In 2011, the 
proportions of mCRPC patients who were treated with regimens containing H1, H2 
and H3 were 93%, 43% and 12% respectively. In 2013, the proportions of mCRPC 
patients who were treated with regimens containing H1, H2 and H3 were 86%, 37% 
and 35% respectively. Between 2011 and 2013, the proportions of patients treated with 
a regimen containing docetaxel increased from 14% to 22% and the proportions of 
patients receiving an injectable BTA increased from 42% to 66%. In this period, the 
average age of patients treated with docetaxel was 69 years while that of patients 
treated with an H3 was 73 years. cOnclusiOns: With the introduction of the new 
agents, a greater proportion of mCRPC patients are treated with a regimen contain-
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postmenopausal women attending a clinic in Western New York, to undergo mammo-
graphic assessment. Eligible participants included women without cancer, no recent 
use of hormone-replacement therapy, and no history of breast augmentation or breast 
reduction surgery. A self-administered questionnaire was used to obtain information 
on demographics, anthropometry, and breast cancer risk factors. Percent density (PD) 
was measured using computer-assisted assessment of mammographic films. General 
linear models were used to test for differences in PD by smoking variables while 
adjusting for selected covariates (age, body mass index, age at first live birth, age at 
menopause, use of hormone therapy, level of education, and family history of breast 
cancer). Results: Study participants (n= 229) included 125 never-smokers, 87 former 
smokers, and 17 current smokers. Current smokers had a lower mean percent density 
(SE) compared to non-current smokers and former smokers (29.6 (5.1) vs. 34.8 (3.9) 
and 37.5 (4.1) p= 0.09). Among ever smokers, age at smoking initiation was inversely 
associated with percent density (P= 0.002). No significant associations were observed 
for the other smoking variables. cOnclusiOns: Younger age at smoking initiation is 
associated with higher PD while current smoking is associated with lower PD. These 
findings suggest that smoking may have differential effects on risk of postmenopau-
sal breast cancer depending on the timing of exposure.
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aPPlyiNg daTa aNalyTiCs To valuE-basEd CaNCEr CarE: EffECTs aNd 
CosT of hosPiTal rEENCouNTErs followiNg CaNCEr surgEry
James T1, Jones C.1, Lafrance D.2, Nix M.E.2
1University of Vermont, Burlington, VT, USA, 2Fletcher Allen, Burlington, VT, USA
Objectives: Surgery is a standard modality in the modern management of solid 
tumors. Unfortunately, some patients will experience unplanned readmissions and 
ED visits following their operation. Emerging trends in health reform have intro-
duced new financial detriments to hospital reencounters in addition to the negative 
impact on quality of care. Our objective was to develop an electronic approach to 
assessing unplanned hospital reencounters following common cancer operations 
in order to guide decision-making aimed improving value in our patient popula-
tion. MethOds: The target population for this study was adult cancer patients 
undergoing mastectomy and colectomy operations for cancer. Data were abstracted 
using an Electronic Data Warehouse (EDW) to determine 30-day emergency depart-
ment visits and hospital readmissions following the selected cancer operations. 
The secondary outcome measure was cost of care for patients returning to the 
hospital within 30-days. Results: Among 105 patients undergoing selected breast 
and colon cancer operations from January 1, 2012 to December 31, 2012 the hospital 
reencounter rate was 11.9%. Wound-related complications were responsible for 
73% of these hospital reencounters. Total costs (direct and indirect) for hospital 
reencounters were $210,722.76. cOnclusiOns: Unplanned hospital readmissions 
and emergency department visits following cancer surgery largely result from post-
operative complications. These unplanned reencounters are a costly source of poor 
quality care. Patient-centered, disease-specific efforts to reduce unplanned hospital 
reencounters have the potential to significantly increase quality while decreas-
ing costs. Using data for decision-making in quality improvement is important for 
achieving value in patient care.
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bEvaCizumab-basEd ChEmoThEraPy aNd ThromboTiC EvENTs risk iN 
ColorECTal CaNCEr PaTiENTs: a mETa-aNalysis sTudy of raNdomizEd 
CoNTrollEd Trials
Alahmari A.K., Guo J.J.
University of Cincinnati College of Pharmacy, Cincinnati, OH, USA
Objectives: Bevacizumab is a recombinant, humanized monoclonal antibody that 
hinders the proliferation of new blood vessels in malignant cells. It plays an impor-
tant role in the management of colorectal cancer; however, there is concern about its 
association with the development of thrombosis. The purpose of current study was 
to address the overall risk of thrombotic events in colorectal cancer patients treated 
with Bevacizumab-based chemotherapy as well as the risk of both arterial and 
venous thrombotic events separately. MethOds: PUBMED/MEDLINE database was 
searched to find relevant clinical trials that published in English language between 
the periods January 1st, 2003 and December 31st 2013. Only randomized control tri-
als (RCTs) that compared non-Bevacizumab to Bevacizumab-based chemotherapy 
regimen for the treatment of colorectal cancer and reported thrombotic events 
were included. The relative risk (RR) with 95% confidence intervals of thrombotic 
events was calculated. Because between-study heterogeneity was insignificant, 
the fixed effect model was used to calculate the estimated effect sizes. Results: 
There were a total of 22 randomized clinical trials that have met our search criteria 
with a total of 12,852 patients used for safety analysis calculations. Based on our 
findings, there is a significant risk of overall thrombotic events in Bevacizumab vs 
control treated group RR = 1.315 (95% CI 1.165-1.483, P = < .0001). In terms of venous 
thrombosis, there is a significant risk in Bevacizumab treated patients with a RR 
= 1.256 (95% CI 1.097-1.43, P = 0.0019) compared to control. Finally, a higher risk of 
arterial thrombosis in patients used Bevacizumab vs control treated groups RR = 
1.635 (95% CI 1.1802.264, P = 0.0065). Sensitivity analyses showed no significant dif-
ferences. cOnclusiOns: Bevacizumab-based chemotherapy is significantly asso-
ciated with the development of thrombotic events either as venous or as arterial 
thrombosis. Health care providers are encouraged to consider thrombosis prophy-
laxis regimen and periodically monitoring their patients.
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assoCiaTioN bETwEEN CardiovasCular drugs aNd ColoN CaNCEr
Deshpande G.1, Weiss S.2, Polli J.3, Shaya F.T.4, Zhan M.5, Raufman J.P.3
1HealthCore, Inc., Wilmington, DE, USA, 2DrugLogic, Reston, VA, USA, 3University of Maryland 
Baltimore, Baltimore, MD, USA, 4University of Maryland School of Pharmacy, Baltimore, MD, USA, 
5University of Maryland School of Medicine, Baltimore, MD, USA
Objectives: To determine if cardiovascular (CV) drugs are associated with an 
increased risk of colon cancer (CC) & if the risk for any individual agent differs from 
inhibitors or to ARBs experienced a significantly decreased all-cause mortality risk 
as compared to those who were not (HR= 0.90, 95% CI: 0.85 – 0.95 and HR= 0.92, 95% 
CI: 0.86 – 0.98, respectively). cOnclusiOns: Our population-based study showed 
that the use of ACE inhibitors and ARBs was associated with reduced overall mortal-
ity in patients with pancreatic cancer. Although modest, such benefits may be of 
great clinical importance because of the low overall survival rate seen in patients 
with pancreatic cancer and the relative safety of ACE inhibitors and ARBs. These 
relationships should be further examined in other populations using similar mod-
eling techniques.
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burdEN aNd TimiNg of firsT aNd subsEquENT skElETal rElaTEd EvENTs 
(srEs) iN uNiTEd sTaTEs EldErly mEN wiTh mETasTaTiC ProsTaTE CaNCEr 
(mPC)
Abdulhalim A.M.1, Hussain A.2, Mullins C.D.1, Qian Y.3, Arellano J.3, Balakumaran A.3, 
Onukwugha E.1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School 
of Medicine, Baltimore, MD, USA, 3Amgen Inc., Thousand Oaks, CA, USA
Objectives: SREs are common in men with mPC and some individuals experi-
ence multiple SREs. We estimated the burden and timing of SREs in elderly men 
diagnosed with mPC. MethOds: We analyzed elderly men diagnosed with mPC 
between 2000-2009 in the SEER-Medicare datasets and followed through 12/31/2010 
or until lost to follow-up. Post-diagnosis SREs were identified using claims that 
indicated spinal cord compression (SCC), pathologic fracture (PF), surgery to bone 
(SB), or radiation (RAD, potentially suggestive of bone palliative radiation). Results: 
Among 8,997 mPC men with a median follow up of 18 months, 4,176 (47.7%) expe-
rienced at least one SRE. The median (mean) time from mPC diagnosis to first SRE 
was 154 (335) days. The median times from mPC diagnosis to first RAD, PF, SCC, or 
SB were 204, 96, 44, or 85 days, respectively. Of the 4,176 men who had at least one 
SRE, 2,619 (62.7%) had a subsequent SRE and 1,442 (35%) had a subsequent SRE of 
a different type. The median (mean) time from first SRE to any second SRE was 23 
(108) days, while it was 21 (177) days from first SRE to second SRE of a different type. 
Subsequent SRE patterns varied considerably depending on the first SRE type. The 
majority of patients who experienced a PF or SCC first quickly had SB within 2 days 
or RAD within a month. cOnclusiOns: The median time from first SRE to second 
SRE was considerably shorter than the median time from mPC diagnosis to first SRE, 
suggesting that once patients have had an SRE, it is quicker to develop subsequent 
SREs. Individuals who had a PF or SCC as a first SRE received RAD or SB within one 
month. These findings provide additional data to guide monitoring and prevention 
of SREs in the elderly mPC population.
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EsTimaTiNg yEars of lifE losT duE To advaNCEd mElaNoma iN 12 
CouNTriEs
Thiam A.1, Zhao Z.2, Weaver R.1, Quinn C.1, Barber B.3
1PRMA Consulting, Fleet, UK, 2Amgen Inc, Thousand Oaks, CA, USA, 3Amgen, Inc., Thousand 
Oaks, CA, USA
Objectives: Advanced (stage IIIB/C and IV) melanoma is an aggressive, deadly 
disease and has a high detrimental impact on patients and society, primarily due 
to premature death. Understanding the burden of advanced melanoma is therefore 
important for health policy and allocating appropriate health care resources to 
treatment. There is limited data available specifically related to burden of advanced 
melanoma on patients. The aim of this study was to estimate years of life lost in 
patients with advanced melanoma in 12 countries. MethOds: Population growth 
and life expectancy were estimated from OECD data and country-specific life tables, 
respectively. Incidence and mortality data for advanced melanoma were collected 
from local cancer registries and GLOBOCAN 2008. Population growth and incidence 
rates by stage of disease were used to estimate the growth in the size of the mela-
noma patient population and new cases of advanced melanoma in 2014, respec-
tively. Melanoma-specific mortality rates were used to estimate the number of 
patients surviving from previous years, to calculate prevalence, mortality and age at 
death for patients with advanced melanoma. Age and sex-adjusted life tables were 
subsequently used to estimate years of life lost for these patients. Results: Years 
of life lost due to advanced melanoma per patient were as follows: Australia (men: 
19.9 years, women: 22.7 years); Brazil (16.3, 19.8); Canada (19.4, 22.3); France (18.8, 
23.1); Germany (18.3, 20.8); Italy (19.3, 22.7); Mexico (17.2, 19.0); the Netherlands (18.5, 
21.5); Spain (19.2, 23.1); Sweden (19.4, 22.0); UK (18.7, 21.2); US (17.9, 20.6). Country 
differences were primarily driven by melanoma mortality rates and disease-free 
life expectancy. cOnclusiOns: This study estimated the years of life lost due to 
advanced melanoma in 12 countries and found variations across countries and vari-
ations between sexes; however, the burden of advanced melanoma is substantial 
in all of the countries.
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mammograPhiC dENsiTy iN assoCiaTioN wiTh smokiNg sTaTus aNd 
smokiNg hisToriEs iN a samPlE of PosTmENoPausal womEN: rEsulTs 
from a Cross-sECTioNal sTudy
Majercak K.1, Nghiem E.2, Byrne C.3, Muti P.4, Barba M.5, Lavigne J.6, Faupel-Badger J.6,  
Teter B.7, Fuhrman B.1
1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2University of Maryland, 
College Park, MD, USA, 3Uniformed Services University, Bethesda, MD, USA, 4McMaster 
University, Hamilton, ON, Canada, 5Italian National Cancer Institute, Rome, Italy, 6Division 
of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 
Department of Health and Human Services, Bethesda, MD, USA, 7University of Buffalo, Buffalo, 
NY, USA
Objectives: Tobacco contains numerous carcinogens, including several known to 
cause mammary tumors in animal models. Our study aimed to investigate whether 
mammographic density (MD), a recognized risk factor associated with breast cancer, 
is influenced by smoking history. MethOds: This was a cross-sectional study of 
